BO21977 Trastuzumab-MCC-DM1(T-DM1) vs Capecitabine + Lapatinib in MBC

• Research type

  Research Study

• Full title

  A randomised, multi-centre, phase III, open label study of the efficacy and safety of Trastzumab-MCC-DM1 vs. Capecitabine plus Lapatinib in patients with HER2-positive Locally Advanced or Metastatic Breast Cancer who have received prior Trastuzumab based therapy.

• IRAS ID

  15684

• Contact name

  David W Miles

• Contact email

  david.miles@doctors.org.uk

• Sponsor organisation

  Genentech Inc. (Lead sponsor and sponsor for USA sites)

• Eudract number

  2008-005-713-22

• Clinicaltrials.gov Identifier

  NCT00829166

• Research summary

  Research Summary not published at request of researcher

• REC name

  North West - Haydock Research Ethics Committee

• REC reference

  09/H1010/22

• Date of REC Opinion

  21 May 2009

• REC opinion

  Further Information Favourable Opinion